Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEC vs FEC Neoadjuvant Therapy in Breast Cancer
NCT02115152Phase 2Unknown
- Sponsor
- Guangxi Medical University
- Start
- Jun 2014
- Primary completion
- Jun 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by Guangxi Medical University. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02115152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115152.